Results From the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2019.02.008
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Elsevier BV